S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:ACRS

Aclaris Therapeutics Stock Forecast, Price & News

$21.31
+0.17 (+0.80 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.85
Now: $21.31
$21.90
50-Day Range
$5.88
MA: $19.69
$24.21
52-Week Range
$0.70
Now: $21.31
$25.48
Volume605,874 shs
Average Volume3.98 million shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics logo

Headlines

Gaining Ground After A Tough Couple Of Weeks
January 25, 2021 |  finance.yahoo.com
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021 |  finance.yahoo.com
Stock Alert: Aclaris Therapeutics Surges 160%
January 19, 2021 |  nasdaq.com
Is ACRS A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933
Employees75
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.23 million
Book Value$1.69 per share

Profitability

Net Income$-161,350,000.00
Net Margins-941.07%

Miscellaneous

Market Cap$1.10 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.81 out of 5 stars

Medical Sector

1154th out of 1,972 stocks

Pharmaceutical Preparations Industry

524th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$21.31
+0.17 (+0.80 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

What stocks does MarketBeat like better than Aclaris Therapeutics?

Wall Street analysts have given Aclaris Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aclaris Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a increase in short interest in February. As of February 12th, there was short interest totaling 1,450,000 shares, an increase of 52.7% from the January 28th total of 949,600 shares. Based on an average daily volume of 2,990,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 3.9% of the shares of the stock are sold short.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings data on Wednesday, February, 24th. The biotechnology company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.01. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 104.00% and a negative net margin of 941.07%.
View Aclaris Therapeutics' earnings history
.

How has Aclaris Therapeutics' stock price been impacted by Coronavirus?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACRS stock has increased by 1,910.4% and is now trading at $21.31.
View which stocks have been most impacted by COVID-19
.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 51, Pay $715.5k)
  • Mr. Frank Ruffo, Co-Founder, CFO & Treasurer (Age 55, Pay $510.89k)
  • Dr. David N. Gordon, Chief Medical Officer (Age 52, Pay $529.07k)
  • Ms. Kamil Ali-Jackson Esq., J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 62)
  • Dr. Joseph Monahan, Chief Scientific Officer
  • Dr. Michael Steven Tung M.D., Sr. VP of Corp. Strategy/Investor Relations (Age 47)
  • Ms. Sheila Kennedy, VP of Marketing
  • Mr. Kevin Scott, VP of Sales
  • Mr. Jeffrey Wayne, Interim Head of Commercial
  • Mr. Gary DeCrescenzo, Sr. VP of Pharmaceutical R&D

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (7.61%), Samsara BioCapital LLC (3.17%), Endurant Capital Management LP (2.63%), BlackRock Inc. (2.27%), Ghost Tree Capital LLC (1.51%) and ExodusPoint Capital Management LP (0.52%).
View institutional ownership trends for Aclaris Therapeutics
.

Which institutional investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Endurant Capital Management LP, Renaissance Technologies LLC, BlackRock Inc., Jane Street Group LLC, Creative Planning, Northern Trust Corp, and Bank of New York Mellon Corp.
View insider buying and selling activity for Aclaris Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Aclaris Therapeutics stock?

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, ExodusPoint Capital Management LP, Verition Fund Management LLC, Citigroup Inc., Wells Fargo & Company MN, Quantitative Systematic Strategies LLC, One68 Global Capital LLC, and Virtu Financial LLC.
View insider buying and selling activity for Aclaris Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $21.31.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $1.10 billion and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 75 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.